

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



同方康泰產業集團有限公司
Tongfang Kontafarma Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

PROFIT WARNING

This announcement is made by Tongfang Kontafarma Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to the profit warning announcement of the Company dated 3 June 2020 and supplemental announcement thereto dated 4 June 2020 (the “**Previous Announcements**”).

Further to the Previous Announcements, the board of directors (the “**Board**”) of the Company wishes to update the shareholders of the Company (the “**Shareholders**”) and potential investors of the Group that based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2020 and the latest assessment on the performance of business segments of the Group, (i) the Group is expected to record a consolidated profit before taxation for the six months ended 30 June 2020 in the region of approximately HK\$22.0 million to HK\$32.0 million, representing a decrease of approximately 38.9% to 11.2% respectively as compared to the consolidated profit before taxation of approximately HK\$36.0 million for the corresponding period in 2019; and (ii) the Group is expected to record a consolidated loss after taxation in the region of approximately HK\$12.0 million to HK\$16.0 million, representing a decrease of approximately 244.1% to 292.1% respectively as compared to the consolidated profit after taxation of approximately HK\$8.3 million for the corresponding period in 2019.

The Board considers that the update on the expected financial results from those disclosed in Previous Announcements was mainly attributable to the resumption of normal operation and production capacity by members of the Group in the pharmaceutical and health business segment in the second quarter in 2020. The Group will closely monitor the situation in the pharmaceutical and health business segment and other business segments in the second half of 2020.

The information contained in this announcement is based on the latest assessment by the management of the Company according to the unaudited consolidated management accounts of the Group for the six months ended 30 June 2020 and taking into account of the latest assessment on the performance of the aforesaid business segment and may be subject to amendments. Therefore, the actual results of the Group for the six months ended 30 June 2020 may differ from the information contained in this announcement.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board of
Tongfang Kontafarma Holdings Limited
Huang Yu
Chairman

Hong Kong, 25 August 2020

As at the date of this announcement, the Board comprises two executive Directors, namely Mr. Huang Yu (Chairman) and Mr. Jiang Chaowen (Chief Executive Officer); and three independent non-executive Directors, namely Mr. Chan Sze Chung, Mr. Zhang Ruibin and Mr. Zhang Junxi Jack.